Health Care [ 4/12 ] | Pharmaceuticals [ 9/75 ]
NASDAQ | Common Stock
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.
Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 26 | 0.19 Increased by +1.05 K% | 0.18 Increased by +5.56% |
| Nov 6, 25 | 0.04 Increased by +100.00% | 0.11 Decreased by -63.64% |
| Aug 7, 25 | -0.10 Increased by +16.67% | 0.01 Decreased by -1.10 K% |
| Jun 11, 25 | -0.06 Decreased by -100.00% | -0.02 Decreased by -200.00% |
| Mar 18, 25 | -0.02 Increased by +77.78% | -0.00 Decreased by -506.06% |
| Nov 12, 24 | 0.02 Increased by +200.00% | -0.01 Increased by +300.00% |
| Aug 8, 24 | -0.12 Decreased by -180.00% | -0.07 Decreased by -71.43% |
| May 9, 24 | -0.03 Increased by +70.00% | -0.07 Increased by +57.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 21.28 M Increased by +82.72% | 1.48 M Increased by +347.99% | Increased by +6.97% Increased by +235.73% |
| Sep 30, 25 | 22.46 M Increased by +117.54% | -1.93 M Decreased by -407.34% | Decreased by -8.58% Decreased by -241.28% |
| Jun 30, 25 | 18.93 M Increased by +108.60% | -2.58 M Increased by +15.00% | Decreased by -13.66% Increased by +59.25% |
| Mar 31, 25 | 17.28 M Increased by +116.95% | -1.57 M Decreased by -93.83% | Decreased by -9.10% Increased by +10.65% |
| Dec 31, 24 | 11.65 M Increased by +59.26% | -598.00 K Increased by +73.49% | Decreased by -5.13% Increased by +83.36% |
| Sep 30, 24 | 10.32 M Increased by +46.90% | 627.00 K Increased by +208.29% | Increased by +6.07% Increased by +173.72% |
| Jun 30, 24 | 9.07 M Decreased by -24.36% | -3.04 M Decreased by -166.70% | Decreased by -33.51% Decreased by -188.19% |
| Mar 31, 24 | 7.97 M Increased by +50.19% | -811.00 K Increased by +69.51% | Decreased by -10.18% Increased by +79.70% |